GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Unity Biotechnology Inc (NAS:UBX) » Definitions » PB Ratio
中文

Unity Biotechnology (Unity Biotechnology) PB Ratio : 0.87 (As of Apr. 24, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Unity Biotechnology PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-24), Unity Biotechnology's share price is $1.47. Unity Biotechnology's Book Value per Share for the quarter that ended in Dec. 2023 was $1.69. Hence, Unity Biotechnology's PB Ratio of today is 0.87.

The historical rank and industry rank for Unity Biotechnology's PB Ratio or its related term are showing as below:

UBX' s PB Ratio Range Over the Past 10 Years
Min: 0.36   Med: 1.16   Max: 4.77
Current: 0.87

During the past 8 years, Unity Biotechnology's highest PB Ratio was 4.77. The lowest was 0.36. And the median was 1.16.

UBX's PB Ratio is ranked better than
82.67% of 1310 companies
in the Biotechnology industry
Industry Median: 2.38 vs UBX: 0.87

During the past 12 months, Unity Biotechnology's average Book Value Per Share Growth Rate was -57.10% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -52.30% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -46.10% per year.

During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of Unity Biotechnology was -37.00% per year. The lowest was -52.30% per year. And the median was -46.40% per year.

Back to Basics: PB Ratio


Unity Biotechnology PB Ratio Historical Data

The historical data trend for Unity Biotechnology's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Unity Biotechnology PB Ratio Chart

Unity Biotechnology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial 2.82 3.37 1.54 0.69 1.14

Unity Biotechnology Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.69 0.40 0.75 0.97 1.14

Competitive Comparison of Unity Biotechnology's PB Ratio

For the Biotechnology subindustry, Unity Biotechnology's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Unity Biotechnology's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Unity Biotechnology's PB Ratio distribution charts can be found below:

* The bar in red indicates where Unity Biotechnology's PB Ratio falls into.



Unity Biotechnology PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Unity Biotechnology's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=1.47/1.692
=0.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Unity Biotechnology  (NAS:UBX) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Unity Biotechnology PB Ratio Related Terms

Thank you for viewing the detailed overview of Unity Biotechnology's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Unity Biotechnology (Unity Biotechnology) Business Description

Traded in Other Exchanges
Address
285 East Grand Avenue, South San Francisco, CA, USA, 94080
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases.
Executives
Anirvan Ghosh director, officer: Chief Executive Officer C/O UNITY BIOTECHNOLOGY, INC., 285 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Jamie Dananberg officer: Chief Medical Officer 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005
Michael P. Samar director C/O ASSEMBLY BIOSCIENCES, INC., 11711 N. MERIDIAN ST. SUITE 310, CARMEL IN 46032
Alexander Hieu Nguyen officer: See Remarks C/O UNITY BIOTECHNOLOGY, INC., 285 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Nathaniel E David director, officer: President C/O KYTHERA BIOPHARMACEUTICALS, INC., 27200 WEST AGOURA ROAD, SUITE 200, CALABASAS CA 91301
Gilmore Neil O'neill director 215 FIRST STREET, CAMBRIDGE MA 02142
Alexander Azoy officer: See Remarks 30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Lynne Marie Sullivan officer: See Remarks C/O SOLID BIOSCIENCES, LLC, 141 PORTLAND STREET, FIFTH FLOOR, CAMBRIDGE MA 02139
Robert Nelsen director 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Graham K Cooper director C/O RECEPTOS, INC., 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
Paul L Berns director 11080 CIRCLEPOINT RD., STE, 200, WESTMINSTER CO 80020
Camille D Samuels director 2463 JACKSON ST., SAN FRANCISCO CA 94115
Kristina Burow director 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
David L. Lacey director 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005
Dan Marquess officer: Chief Scientific Officer 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005